← Search another drug
PatientPulse · by PatientPartner
Verzenio abemaciclib
High confidence
~51 public patient conversations, blogs, forum threads, and review pages analyzed; an estimated 300+ individual patient voices represented across multi-reply forum threads.
Executive intelligence
The signal that moves starts & adherence
45%Positive sentiment in discussion
18,718FDA adverse-event reports
52%Flagged serious
97%Reports name female patients
Diarrhea is not just the top side effect, it is the primary adherence-breaker and the single loudest patient voice in every forum; a structured dose-titration and bowel-management support program could protect completion rates across the full two-year course.
- Diarrhea dominates patient discourse at every stage, with many describing an unmanageable diarrhea-to-constipation oscillation that forces dose reductions or temporary discontinuation within the first three months.
- The $14,000 per month list price creates acute middle-class access anxiety; patients who do not qualify for Lilly assistance programs frequently consider switching to Kisqali or Ibrance purely on affordability grounds.
- Fatigue and cognitive fog are the second-tier complaints that erode work, caregiving, and social function over the full two-year course, often described as more disruptive than the GI effects once the bowel issues stabilize.
- Despite the burden, a strong majority of completers express retrospective gratitude and recommend the drug, framing side-effect management as learnable craft rather than a reason to stop treatment.